Our portfolio includes companies on the cutting edge of innovation with solutions that improve clinical outcomes and have a true financial impact on the healthcare system.
I am a technology guy and a first time CEO. Triventures helped me fill in the blanks, think through ideas and see the big picture.
Triventures is a true partner. They are with you when you are up and they are with you when you are down. Their perseverance, support and guidance allowed us to get to where we needed to be.
We couldn’t have turned to a better VC. Their interventional cardiology know-how and industry relationships are off the charts.
It was great to have Triventures as our lead investor. They helped us put together a syndication in which each partner added unique value.
The key added value you want from your investors is for them to become a true partner. You want them to work with you at your side, and together make your company a success. Not many VCs do that… Triventures certainly does.
Triventures believed in us when we were just an idea. Now we have the first image-guided robotic positioning system in the world helping laparoscopic surgeons deliver better care.
Triventures offers more than just financial support. I truly believe we wouldn’t be where we are today, and where we are headed without their advice and relationships.
It is comforting to know that I can call on them at any time of the day on any issue. There is a new challenge every day and they are like the seasoned specialist who is always on call, ready to give a helping hand.
Any medtech venture would be wise to partner with them. They can help you at every stage in the life of a healthcare start up, from crafting IP all the way to executing a sound bizdev strategy.
6over6 is developing a suite of smartphone optometry tools. With its application, anyone anywhere can obtain a complete prescription, pupillary distance (PD), and astigmatism from any smartphone.
Apica and its spinout ApK developed a suite of implant devices designed to improve transapical surgical access and left ventricular assist device implantation. The companies were acquired by Thoratec in July 2014.
Cathworks is developing an image-based approach for assessing FFR (functional flow reserve) in the cath lab using data from standard angiograms.
Eyeyon has developed a therapeutic contact lens platform for chronic corneal edema and other corneal-related disorders and post-operative procedures. Eyeyon is also developing a synthetic fluid barrier that has the potential to displace a difficult cadaver based corneal endothelial transplantation procedure, with a simple, easy to implant off the shelf synthetic product.
LifeBeam is developing ‘Hearable’ headsets with embedded sensors to assess physiological parameters in real-time and artificial intelligence algorithms that learn user preferences and act as a virtual trainer.
V-Wave is developing a minimally invasive device for heart failure. The device regulates left atrial pressure (LAP) by shunting excess blood volume away from the left ventricle – the heart’s main pumping chamber.